BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 21, 2016--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing CODIT™ (Characterized Oral Desensitization
ImmunoTherapy) treatments for life-threatening food
allergies, today announced that it will host an Investor Symposium in
New York City on December 1, 2016. The event will bring together leading
experts to discuss the emerging treatment landscape in peanut allergy.
Topics will include a historical overview of immunotherapy approaches,
considerations for developing regulated treatment options, Phase 2 data
and experience with AR101, and treatment expectations in the
peanut-allergic community. The Aimmune management team will also provide
a corporate and clinical update and review upcoming milestones. A
question and answer session will follow the formal presentations. AR101
is Aimmune’s investigational oral biologic desensitization therapy for
peanut allergy, which is currently in Phase 3 clinical development.
Guest Physician Presenters
George Du Toit, MD, is lead author of the LEAP and LEAP-On
hallmark studies that showed feeding peanuts to young children can
sharply reduce the risk of their developing peanut allergies. Dr. Du
Toit is currently an Honorary Senior Lecturer at King's College London
and a Pediatric Allergy Consultant in London at Guy's and St. Thomas'
NHS Foundation Trust, which is home to one of Europe's largest
specialist children's allergy centers. He is also Chair of the Pediatric
Section of the European Academy of Allergy and Clinical Immunology
(EAACI). His research interests concern the prevention of food allergy,
urticarial disorders, exercise and allergy, and allergy to medications
Stanley M. Fineman, MD, MBA, has been in private allergy practice
for 35 years and is currently a physician at Atlanta Allergy & Asthma.
He earned his medical degree from Emory University School of Medicine
and completed his internship and residency in Pediatrics at the
University of Cincinnati, followed by an Allergy and Immunology
fellowship at Harvard University School of Medicine. Dr. Fineman is a
past president of the American College of Allergy, Asthma and Immunology
and the American Academy of Pediatrics.
Edwin Kim, MD, is Assistant Professor of Medicine and Pediatrics
at the University of North Carolina (UNC) School of Medicine. Dr. Kim is
also the Director of the UNC Food Allergy Initiative and the director of
the UNC allergy and immunology fellowship training program. Dr. Kim
gained significant research experience in food allergy while training at
Duke and UNC under Dr. Wesley Burks. He earned his MD at Rutgers Robert
Wood Johnson Medical School. Dr. Kim also earned an MS in Health Policy
and Management from the Harvard School of Public Health and a BS in
Biology from the Massachusetts Institute of Technology.
Event and Webcast Details
The Investor Symposium will be held on Thursday, December 1, 2016, from
8:00-10:30 a.m. Eastern Time in New York City. Analysts and investors
may register for the event by contacting LifeSci Advisors, LLC, at email@example.com.
A live webcast of the event may be accessed in the Investor Relations
section of Aimmune’s website at www.aimmune.com
under the Events page. A replay will be available for at least 30 days.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of protection
by desensitizing patients with defined, precise amounts of key
allergens. Aimmune’s first investigational product using CODIT™, AR101
for the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age and is currently being evaluated in Phase 3 clinical
trials in ages 4-55. AR101 is a characterized, regulated, oral
biological drug product containing the protein profile found in peanuts.
For more information, please see www.aimmune.com.
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding: Aimmune’s expectations regarding the potential
benefits of AR101; and Aimmune’s expectations regarding potential
applications of the CODIT™ approach to treating life-threatening food
allergies. Risks and uncertainties that contribute to the uncertain
nature of the forward-looking statements include: the possibility that
Aimmune’s clinical trials will not be successful; Aimmune’s dependence
on the success of AR101; the company’s reliance on third parties for the
manufacture of the company’s product candidates; possible regulatory
developments in the United States and foreign countries; and the
company’s ability to attract and retain senior management personnel.
These and other risks and uncertainties are described more fully in
Aimmune's most recent filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year ended
2015 and Quarterly Report on Form 10-Q for the quarter ended September
30, 2016. All forward-looking statements contained in this press release
speak only as of the date on which they were made. Aimmune undertakes no
obligation to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or the European Medicines Agency
(EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161121005357/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,